Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
Benjamin M. Ellingson, Martin Bendszus, Jerrold L. Boxerman et al. · Neuro-Oncology · 2015
A recent joint meeting was held on January 30, 2014, with the US Food and Drug Administration (FDA), National Cancer Institute (NCI), clinical scientists, imaging experts, pharmaceutical and biotech companies, clinical trials cooperative groups, and patient advocate groups to discuss imaging endpoints for clinical trials in glioblastoma. This workshop developed a set of priorities and action items including the creation of a standardized MRI protocol for multicenter studies. The current document outlines consensus recommendations for a standardized Brain Tumor Imaging Protocol (BTIP), along with the scientific and practical justifications for these recommendations, resulting from a series of discussions between various experts involved in aspects of neuro-oncology neuroimaging for clinical trials. The minimum recommended sequences include: (i) parameter-matched precontrast and postcontrast inversion recovery-prepared, isotropic 3D T1-weighted gradient-recalled echo; (ii) axial 2D T2-weighted turbo spin-echo acquired after contrast injection and before postcontrast 3D T1-weighted images to control timing of images after contrast administration; (iii) precontrast, axial 2D T2-weighted fluid-attenuated inversion recovery; and (iv) precontrast, axial 2D, 3-directional diffusion-weighted images. Recommended ranges of sequence parameters are provided for both 1.5 T and 3 T MR systems.
Cited by 663 works. doi:10.1093/neuonc/nov095 Open-access PDF
Authors
- Benjamin M. Ellingson
- Martin Bendszus
- Jerrold L. Boxerman
- Daniel P. Barboriak
- Bradley James Erickson
- Marion Smits
- Sarah J. Nelson
- Elizabeth Robins Gerstner
- Brian Michael Alexander
- Gregory Goldmacher
- Wolfgang Wick
- Michael A. Vogelbaum
- Michael Weller
- Evanthia Galanis
- Jayashree Kalpathy–Cramer
- Lalitha Krishna Shankar
- Paula M. Jacobs
- Whitney B. Pope
- Dewen Yang
- Caroline D. Chung
References
- Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010
- Response criteria for phase II studies of supratentorial malignant glioma.
- Tumor Detection by Nuclear Magnetic Resonance
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- Recognition of Cancer in vivo by Nuclear Magnetic Resonance
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods
- Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
- Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response.